Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Abstract Background Olaparib (Lynparza™) is a PARP inhibitor approved for advanced
BRCA-mutated (BRCA m) ovarian cancer. PARP inhibitors may benefit patients whose …
BRCA-mutated (BRCA m) ovarian cancer. PARP inhibitors may benefit patients whose …
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
SE Willis, C Winkler, MP Roudier, T Baird… - British Journal of …, 2021 - nature.com
Background The absence of the putative DNA/RNA helicase Schlafen11 (SLFN11) is
thought to cause resistance to DNA-damaging agents (DDAs) and PARP inhibitors. Methods …
thought to cause resistance to DNA-damaging agents (DDAs) and PARP inhibitors. Methods …